Reviva Pharmaceuticals Warrants
RVPHW
RVPHW was delisted on the 12th of December, 2025.
8 hedge funds and large institutions have $1.45M invested in Reviva Pharmaceuticals Warrants in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
20% less funds holding
Funds holding: 10 → 8 (-2)
35% less capital invested
Capital invested by funds: $2.22M → $1.45M (-$768K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$901 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$27 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
-$244K |
| 2 |
6CM
683 Capital Management
New York
|
-$102K |
| 3 |
ICM
Ionic Capital Management
New York
|
-$69K |
| 4 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$25.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
1
BlueCrest Capital Management
St Helier,
Jersey
| $488K | – | – | – |
|
|
ASM
2
ATW SPAC Management
New York
| $438K | – | – | – |
|
|
BFM
3
Boothbay Fund Management
New York
| $438K | – | – | – |
|
|
AA
4
AQR Arbitrage
Greenwich,
Connecticut
| $57K | -$25.1K | -59,593 | -29% |
|
5
Walleye Trading
New York
| $26K | – | – | – |
|
6
Walleye Capital
New York
| $36 | – | – | – |
|
|
GCL
7
Glazer Capital LLC
New York
| – | -$244K | -480,459 | Closed |
|
|
6CM
8
683 Capital Management
New York
| – | -$102K | -200,000 | Closed |
|
|
ICM
9
Ionic Capital Management
New York
| – | -$69K | -135,481 | Closed |
|
|
10
UBS Group
Zurich,
Switzerland
| – | +$27 | +64 | +38% |
|
|
WAM
11
Wolverine Asset Management
Chicago,
Illinois
| – | +$901 | +2,141 | New |
|
RVPHW Hedge Fund Activity: Q3 2021 in Review
8 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q3 2021, worth a combined $1.45M — down 35% from $2.22M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of RVPHW and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Wolverine Asset Management, opening a new position worth an estimated $901. The largest seller was Glazer Capital LLC, exiting entirely with an estimated $244K sold.
- 8 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q3 2021, down from 10 in Q2 2021.
- Funds reported $1.45M of Reviva Pharmaceuticals Warrants stock for Q3 2021, down 35% quarter-over-quarter.
- 1 fund opened new Reviva Pharmaceuticals Warrants positions in Q3 2021 and 3 closed out, a net change of -2 holders.
- The largest Reviva Pharmaceuticals Warrants buyer in Q3 2021 was Wolverine Asset Management, an estimated $901 added.
- The largest Reviva Pharmaceuticals Warrants seller in Q3 2021 was Glazer Capital LLC, an estimated $244K sold.
Based on aggregated 13F filings for Q3 2021.